Merck: Phase 3 Study of Antibacterial Recarbrio Meets Key Endpoints
30 September 2019 - 1:39PM
Dow Jones News
By Colin Kellaher
Merck & Co. (MRK) on Monday said a pivotal phase 3 study of
its antibacterial product Recarbrio met its main endpoints in
adults with hospital-acquired bacterial pneumonia and
ventilator-associated bacterial pneumonia.
The Kenilworth, N.J., drug maker said Recarbrio met the primary
endpoint of statistical non-inferiority compared to
piperacillin/tazobactam in day 28 all-cause mortality and the
secondary endpoint of clinical response at early follow up in the
modified intent-to-treat population.
Merck said it plans to present the full data from the trial at a
scientific congress next year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 30, 2019 07:24 ET (11:24 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024